Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is indicated for certain blood‑cancer subtypes and works by modulating the immune system, inhibiting new blood‑vessel growth, and promoting cancer‑cell death.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in the treatment of hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones. - Multiple myeloma: improves response rates and prolongs progression‑free survival when combined with other agents. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may achieve cytogenetic remission. - Mantle cell lymphoma: contributes to disease control as part of combination therapy.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Rash: skin redness or itching. - Constipation: difficulty passing stool. - Nausea: feeling of sickness often without vomiting. - Peripheral edema: swelling of extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmias: irregular heart rhythms requiring monitoring.

Before initiating therapy, clinicians should assess patient history and monitor laboratory parameters. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombo‑risk: evaluate need for prophylactic anticoagulation in high‑risk patients. - Renal function: adjust monitoring for patients with impaired kidney function. - Hepatic function: monitor liver enzymes regularly. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Lenalidomide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Immunosuppressants (e.g., cyclosporine): heightened infection risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate renal toxicity. - P‑glycoprotein substrates: potential alteration of drug levels. - Vaccines: live vaccines should be avoided during treatment. - Hormonal contraceptives: efficacy may be reduced, consider additional methods.